Skip to main content
Equibles
INMB logo

INMB · Inmune Bio, Inc.

Track INMB — free

Use INMB with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

Claude ChatGPT Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$2.44 +0.17 (+7.49%) At close · Sep 4
Rebalance outlook locked
Going-concern doubt — flagged Aug 6, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These conditions and events raise substantial doubt about the Company's ability to continue as a going concern. ... Because management's plans have not yet been finalized and are not within the Company's control, the implementation of such plans cannot be considered probable. As a result, the Company has concluded that management's plans do not alleviate substantial doubt about the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 6, 2026
Market Cap
$67.72M
Shares
27.75M

INMB metrics

57 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$2.44
Market cap
$67.72M

Price action

19 metrics
Price change (1W)
+4.7%
Price change (30D)
+15.1%
Price change (3M)
+93.7%
Price change (6M)
+83.5%
Price change (YTD)
+56.4%
Price change (1Y)
+27.1%
Trailing year
Price change (5Y)
-90.8%
52-week high
$2.45
52-week low
$1.12
Change from 52-week high
-0.2%
Change from 52-week low
+117.9%
Annualized volatility
72.4%
Beta
2.4
RSI (14D)
63.8
Price vs SMA 50
+22.9%
Price vs SMA 200
+52.4%
Avg volume (3M)
704,885
Relative volume
0.5
Average dollar volume
$1.22M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
27.75M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
1,354.4×
reciprocal yield 0.1%
P / book
3.3
reciprocal yield 30.1%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-27.2%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
1,396.8×
reciprocal yield 0.1%
EV / revenue historical average (5Y)
1,076.3×
reciprocal yield 0.1%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-03-31

Profitability

9 metrics
Gross margin
—
Operating margin
-94,766.0%
Trailing 12 months
Net margin
-91,866.0%
Gross profit (TTM)
—
Operating profit (TTM)
−$20.20M
Net income (TTM)
−$18.42M
Trailing 12 months
Diluted EPS (TTM)
$-0.63
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$2.18

Growth

11 metrics
Revenue growth YoY
+257.1%
Year over year
Net income growth YoY
—
Revenue (TTM)
$50,000
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+14.7%
Year over year · more shares
Revenue CAGR (3Y)
-48.9%
Revenue CAGR (5Y)
+35.4%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-90.4%
Return on assets
-68.6%
Debt / equity
—
Current ratio
4.0
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
4.0
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$18.41M
Total assets
$26.84M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$14.96M
Capital expenditures (TTM)
—
R&D (TTM)
$16.66M
SG&A (TTM)
—
Stock compensation (TTM)
$9.15M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
83
13F filer change QoQ
0
Institutional ownership
16.0%

Short interest

3 metrics
Short interest
7.6%
Latest settlement · 5.0 days to cover
Days to cover
5.0d
Short-squeeze score
64 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1711754 CUSIP 45782T105 13F (30d) 54 filings 54 filers Visit website Investor relations